TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Ketorolac for Pain Control in Scleral Buckle Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. consent of the patient or legal guardian~2. 18 years or above~3. normal height and weight~4. ASA class I, II~5. elective surgery~6. surgery time within 60min~7. understanding of the verbal numerical rating score (0-10)~Exclusion Criteria:~1. history of ocular surgery, trauma or infection~2. intraoperative complications~3. glaucoma or ocular hypertension (\> 20 mmHg)~4. diabetic retinopathy~5. diagnosis of asthma or coagulopathy~6. chronic pain syndromes~7. history of peptic ulceration, liver or hematologic disease~8. history of chronic use of analgesics, sedatives, opioids or steroids~9. history of drug or alcohol abuse~10. history of systemic disease~11. sexually transmitted disease (STD)~12. Pregnancy, lactation;~13. cognitive impairment or psychiatric illness;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketorolac Tromethamine (Type: EXPERIMENTAL): On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 minutes before scleral buckle surgery.
- placebo (Type: PLACEBO_COMPARATOR): On operation day, the patients were randomly assigned to receive placebo before scleral buckle surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Specific Effects of Standard Titre Measles Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Infants of 6 months of age registered in the Bandim Health Project registration system and currently living in the Bandim Health Project areas: Bandim I, Bandim II, Belem and Mindará~Exclusion Criteria: Severe illness requiring hospitalisation

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 8 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current patient receiving hemodialysis at two participating dialysis centers who are able to provide informed consent~Exclusion Criteria:~* Not a patient at one of the two participating dialysis centers or not able to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCMH-KD dialysis care (Type: EXPERIMENTAL): Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of T1DM within \>3 and \<24 months of screening according to the American Diabetes Association criteria~* Between 18 and 45 years of age~* Positive test for Epstein-Barr antibody~* Positive test for at least one of the following antibodies:~  * ICA512-antibody~ * ICA~ * GAD65-antibody~ * Insulin (if assessed within 10 days of the onset of insulin therapy)~ * ZnT8~* Peak C-peptide \>0.1 pmol/ml (\>0.3 ng/ml) during MMTT challenge~* Adequate venous access to support draw of 400 ml whole blood and infusion of investigational therapy~Exclusion Criteria:~* Hemoglobin \<10.0 g/dL; leukocytes \<3,000/µL; neutrophils \<1,500/µL; lymphocytes \<800/µL; platelets \<100,000/µL~* Regulatory T cells present in peripheral blood at \<10 per µl as determined by flow cytometry~* Serologic evidence of HIV-1 or HIV-2 infection~* Evidence of current hepatitis B as demonstrated by HBsAg or circulating hepatitis B genomes~* Serologic evidence of hepatitis C infection~* Detectable circulating EBV or CMV genomes or active infection~* Positive PPD skin test defined as greater than or equal to 10 mm induration~* Chronic use of systemic glucocorticoids or other immunosuppressive agents, or biologic immunomodulators within 6 months prior to study entry. Specifically, subjects who have received over 7 days of treatment with 7.5mg of prednisone (or the equivalent) within 6 months prior to study entry will be excluded.~* History of malignancy ( including squamous cell carcinoma of the skin or cervix) except adequately treated basal cell carcinoma~* Any chronic illness or prior treatment which in the opinion of the investigator should preclude participation in the trial~* Pregnant or breastfeeding women, any female who is unwilling to use a reliable and effective form of contraception for 2 years afer Treg dosing and any male who is unwilling to use a reliable and effective form of contraception for 3 months after Treg dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Polyclonal Regulatory T Cells (Type: EXPERIMENTAL): Patients with Type 1 Diabetes Mellitus will have their regulatory T cells (Tregs) isolated by researchers and receive Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells by infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients of age \> 18 years~* Patients with acute cholecystitis based on three of the following signs~  * abdominal pain in the upper right quadrant~ * Murphy's sign~ * leucocytosis \> 10 /ml~ * rectal temperature \> 38 °C or \< 36.5 °C plus~ * cholecystolithiasis (stones / sludge) or sonographic signs of cholecystitis (thickening and triple layer formation of the gall bladder wall)~* Immediate antibiotic therapy (400 mg Moxifloxacin i.v. once a day)~* Laparoscopic cholecystectomy possible within 24 hours after presentation of the patient~* Informed consent~Exclusion Criteria:~* ASA IV and V (table 2)~* Septic shock~* Perforation or abscess of the gall bladder~* Impossibility of laparoscopic surgery (further surgery, surgeon, ...)~* Additional need of antibiotics due to secondary disease~* Known intolerability of Moxifloxacin~* Known or possible pregnancy, breast feeding~* Life-threatening diseases (life-expectancy \< 48 hours)~* End-stage liver disease (Child-Pugh C)~* Psychiatric or severe neurologic disease~* Relevant bradycardia or other symptomatic arrhythmias~* Significant cardiac disease~* Known long QT-disorders~* Electrolyte disorders, especially hypocalcemia~* Known intolerability of chinolones~* Earlier participation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm newborns (gestational age 23-32 weeks) with stage 1 ROP~* A signed parental informed consent~Exclusion Criteria:~* Newborns with heart failure~* Newborns with recurrent bradycardia (heart rate \< 90 beat per minute)~* Newborns with second or third degree atrioventricular block~* Newborns with congenital cardiovascular anomalies, except for persistent ductus arteriosus, patent foramen ovale and small ventricular septal defects~* Newborns with hypotension~* Newborns with renal failure~* Newborns with actual cerebral haemorrhage~* Newborns with other diseases which contraindicate the use of beta-adrenoreceptor blockers.~* Newborns with a more severe stage of ROP than stage 1

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propranolol 0.2% eye drops (Type: EXPERIMENTAL): Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). The treatment will be started as soon as the diagnosis of stage 1 ROP is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days. Cardiovascular and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. Propranolol concentrations will be measured on dried blood spots at the steady state (10th day). Serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and the possible complications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Behavioral Health Homes for Adults With Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 and older~* Serious mental illness (schizophrenia, bipolar disorder, major depression)~* Receive services at one of the 11 participating community mental health centers~* At least one claim for outpatient case management or peer specialist services~Exclusion criteria:~* Not willing to provide informed consent~* Assessed by clinicians as being too ill to be treated on an outpatient basis~* Unable to speak, read, or understand English at the minimum required level

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient Self-Directed Care (Type: ACTIVE_COMPARATOR): See intervention description
- Provider-Supported Integrated Care (Type: ACTIVE_COMPARATOR): See intervention description

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of distal subungual onychomycosis affecting at least one great toenail~* KOH positive at screening~* Willingness not to use any other products including nail polish applied to the toenails during the study~* Women of childbearing potential who are currently sexually active must agree to use contraception for the entire study period~Exclusion Criteria:~* Concurrent or recent use of certain topical or systemic medications without a sufficient washout period~* History of any significant chronic fungal disease other than onychomycosis~* Significant confounding conditions as assessed by study doctor~* Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AN2690 Topical Solution, 5% (Type: EXPERIMENTAL): AN2690 Topical Solution, 5%
- Solution Vehicle (Type: PLACEBO_COMPARATOR): Solution Vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide written consent~* Able to speak and understand English~* Age 18 and older~* Diagnosed with epilepsy~* Diagnosed with serious mental illness (DSM IV diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder or chronic/recurrent depression confirmed with the Mini-International Neuropsychiatric Interview (MINI))~* Receive care at a community mental health center or other publicly funded community healthcare entity~Exclusion Criteria:~* Actively suicidal/homicidal individuals~* Individuals with dementia~* Unable to be rated on study rating scales~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TIME (Type: EXPERIMENTAL): This arm will receive the TIME intervention.
- Treatment as Usual (TAU) (Type: NO_INTERVENTION): This arm will receive treatment as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non-pregnant~* Non menopausal women~* Total femur BMD below -2.5 SD (T score) or lumbar spine BMD below -2.5 SD (T score) or BMD below -1 associated with a vertebral osteoporotic fracture (diminution of vertebral height over 20%)~* HIV infection known for at least 5 years~* CD4 cell count over 50/mm3~* Karnofsky score over or equal to 70~* Written informed consent.~Exclusion Criteria:~* Osteoporosis resulting from a cause other than HIV: vitamin D deficiency (in that case, after receiving high-dose calcium and vitamin D for 1 month, patients will be randomized without a new screening), renal failure, heart failure (NHYA class III or IV), treatment with glucocorticoid at a dose over or equal to 0.5mg/kg/d for 15 days or more at time of inclusion or during the previous 6 months; thyroid or other endocrine disease if untreated for more than 6 months; hypercalciuria~* Testosterone below normal if treatment is hormonal~* BMI below or equal to 18~* Severe lung failure~* Chronic alcohol intoxication~* Ongoing opportunistic infection~* Gastric ulcer of disease interfering with oesophageal motility in the previous 3 months~* History of treatment for osteoporosis~* History of malignancy in the previous 5 years (except skin cancer and Kaposi)~* Cytotoxic chemotherapy or cytokine therapy~* Liver cirrhosis~* Breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Provision of informed consent prior to any study specific procedures~* 2. Female or male aged at least 18 years~* 3. Females of child-bearing potential must have a negative urine pregnancy test at enrolment and be willing to use reliable contraception~* 4. Index event of non-ST or ST segment elevation ACS.~Exclusion Criteria:~* 1.Contraindication or other reason that clopidogrel or ticagrelor should not be administered (eg, hypersensitivity, active bleeding, moderate or severe liver disease, history of previous intracranial bleed, GI bleed within the past 6 months, major surgery within 30 days)~* 2. Oral anticoagulation therapy or GP IIb/IIIa receptor antagonists therapy within 30 days prior to randomisation or cannot be stopped~* 3. Ticagrelor or clopidogrel or other P2Y12 inhibitors within 14 days prior to randomisation~* 4. Requires dialysis~* 5. Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) and prostacyclins (PGI2) therapy that cannot be stopped

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): None
- clopidogrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred for elective or urgent coronary balloon angioplasty or atherectomy with an FDA-approved device in one of the following settings: unstable angina or non-Q wave myocardial infarction, acute Q-wave myocardial infarction, or high-risk clinical/morphological characteristics~Exclusion Criteria:~* Patients with a history of hemorrhagic diathesis - Having had major surgery or clinically significant gastrointestinal or genitourinary bleeding within 6 weeks of study enrollment~* Having had a stroke within 2 years prior to enrollment or any stroke with significant residual neurological deficit~* Having occlusion of the left main coronary artery greater than 50% or a history of vasculitis~* Treated with oral anticoagulants within 7 days (unless prothrombin time is =\< 1.2 times control) or intravenous dextran (before or planned for during the treatment angioplasty)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.
- Abciximab and Placebo (Type: EXPERIMENTAL): Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.
- Abciximab (Type: EXPERIMENTAL): Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have successfully completed the previous double-blind study AGAL-008-00 (NCT00074984)~* Patients must provide written informed consent prior to study participation~* Female patients of childbearing potential must have a negative pregnancy test prior to each dosing and all female patients must use a medically accepted form of contraception throughout the study~Exclusion Criteria:~* The patient was unable to complete AGAL-008-00 (NCT00074984)~* The patient has undergone kidney transplantation or is currently on dialysis~* The patient has diabetes mellitus or presence of confounding renal disease~* The patient has a clinically significant organic disease or an unstable condition that precludes participation~* The patient is unwilling to comply with the protocol requirements

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fabrazyme 1.0 mg/kg every 2 weeks (Type: EXPERIMENTAL): This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete